A new ovarian cancer drug has been submitted for marketing authorization to the European Medicines Agency (EMA) by Swedish firm Oasmia Pharmaceutical.
Oasmia (Nasdaq: OASM) has made the application for its lead cancer product Apealea (also known as Paclical). Apealea is a formulation of paclitaxel based on the patented excipient platform XR-17, which forms micellar nanoparticles with paclitaxel.
Oasmia executive chairman Julian Aleksov said: "After many years of significant efforts by everyone involved in this project, it is with great satisfaction that we are finally able to announce the regulatory filing of an application for marketing authorization of Apealea in the EU. Apealea, once approved, we believe would be able to take a share of the market for cytostatics in EU, which currently amounts to more than 5 billion euros [$5.57 billion] annually."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze